June 3, 2020

Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis

 

Abstract
No known therapies can prevent anaphylaxis. Bruton’s tyrosine kinase (BTK) is an enzyme thought to be essential for high-affinity IgE receptor (FcεRI) signaling in human cells. We tested the hypothesis that FDA-approved BTK inhibitors (BTKi’s) would prevent IgE-mediated responses including anaphylaxis. We showed that irreversible BTKi’s broadly prevented IgE-mediated degranulation and cytokine production in primary human mast cells and blocked allergen-induced contraction of isolated human bronchi.

World Allergy Organization Journal Volume 13, Issue 5 , May 2020

wordmark

Alert: World Allergy Organization Journal

New Articles available on ScienceDirect
Cover Image World Allergy Organization Journal

World Allergy Organization Journal

The allergenic activity and clinical impact of individual IgE-antibody binding molecules from indoor allergen sources

Article Number 100118
Luis Caraballo, Rudolf Valenta, Leonardo Puerta, Anna Pomés, ... Daria Trifonova

June 2, 2020

ATS: Juan C. Celedón, MD, DrPH, ATSF, was installed as president for the 2020-21 term

The ATS installed new officers for the 2020-21 term on Tuesday, May 19, during the ATS 2020 Virtual Plenary Session. Juan C. Celedón, MD, DrPH, ATSF, was installed as president for the 2020-21 term.


May 30, 2020

Season of birth is associated with increased risk of atopic dermatitis in Japanese infants: a retrospective cohort study

Abstract
Background
Several epidemiological studies have examined the possibility of a relationship between season of birth and atopic dermatitis (AD) and food allergy (FA), yet their results are contradictory. We investigated the association between season of birth and risk of AD and FA in Japanese infants.
Methods
Study subjects were 612 newborn infants born at a single obstetric/pediatric clinic without perinatal diseases.

Towards definitive management of allergic rhinitis: best use of new and established therapies



Abstract
Background
Allergic rhinitis (AR) is an inflammatory disease of the nasal mucosa impacting up to 25% of Canadians. The standard of care for AR includes a treatment plan that takes into account patient preferences, the severity of the disease, and most essentially involves a shared decision-making process between patient and provider.
Body
Since their introduction in the 1940s, antihistamines (AHs) have been the most utilized class of medications for the treatment of AR. First-generation AHs are associated with adverse central nervous system (CNS) and anticholinergic side effects.

May 28, 2020

Is diet partly responsible for differences in COVID-19 death rates between and within countries?

  • Review
  • Open Access

  • […]
  • The ARIA group
  • Abstract
    Reported COVID-19 deaths in Germany are relatively low as compared to many European countries. Among the several explanations proposed, an early and large testing of the population was put forward. Most current debates on COVID-19 focus on the differences among countries, but little attention has been given to regional differences and diet. The low-death rate European countries (e.g. Austria, Baltic States, Czech Republic, Finland, Norway, Poland, Slovakia) have used different quarantine and/or confinement times and methods and none have performed as many early tests as Germany. Among other factors that may be significant are the dietary habits.

    Masks & The Moral Matrix | Why We're So Divided Over COVID-19

    Male sex is strongly associated with IgE-sensitization to airborne but not food allergens: results up to age 24 years from the BAMSE birth cohort

    • Research
    • Open Access

    Clinical and Translational Allergy

    Abstract
    Background
    Up to half of the population in high-income countries has allergen-specific IgE antibodies. However, data regarding sex differences of IgE-sensitization from childhood to adulthood is limited.

    May 27, 2020

    Visit EAACI Digital Congress 2020 with us!

    EAACI Digital Congress 2020
    is a new milestone in the long story of Allergy Congresses and we couldn't miss this great event!
    It is our pleasure to invite you to visit the first Bilastine Digital Booth, carefully thought to provide you with relevant scientific content and let you know more about Bilastine, the newest antihistamine worldwide!  


    Aditionally, we would like to invite you to participate in a Real World Clinical Case Challenge.
    We count on your visit to contribute to a great EAACI event.

    Visit EAACI.org
    Or join us at BILASTINA.COM
    Copyright © 2020 Faes Farma, All rights reserved.

    ADVERTENCIA LEGAL
    Este correo electrónico y, en su caso, cualquier fichero anexo al mismo, contiene información de carácter confidencial exclusivamente dirigida a su destinatario. Queda prohibida su divulgación, copia o distribución a terceros sin la previa autorización escrita de Faes Farma, S.A.

    En el caso de haber recibido este correo electrónico por error, se ruega notifíquese inmediatamente esta circunstancia mediante reenvío a la dirección electrónica del remitente.
    De conformidad con lo establecido en la LOPD, Faes Farma, S.A. garantiza la adopción de las medidas necesarias para asegurar el tratamiento confidencial de los datos de carácter personal y el cumplimiento de los dispuesto en el Reglamento General de Protección de Datos (RGPD).
    Si no desea recibir nuestras comunicaciones puede enviarnos un mensaje de correo a nuestro buzón de correo electrónico webmaster@faesfarma.com o pulse aquí.

    This email and any attachements to it contains confidential information exclusively intended for the recipients. Any divulgation, copy or distribution to third parties is prohibited without the written permission of Faes Farma, S.A. If you have received this e-mail in error, please notify the sender immediately.
    In accordance with the Spanish Data Privacy Law (LOPD), Faes Farma, S.A. guarantees that it has adopted the necessary measures to ensure the confidential treatment of personal information and the compliance with the General Data Protection Regulation (GDPR). 

    May 25, 2020

    Concordance for changes in allergic asthma domain variables after short-term corticosteroid therapy

    Research article - Open Access

    BMC Pulmonary Medicine


    Philip E. Silkoff, Mark Sarno, Solomon Ssenyange, Vivek Balasubramanyam, Brian Awabdy & Ryan Leard

    BMC Pulmonary Medicine volume 20, Article number: 139 (2020)

    Abstract

    Background

    Asthma is a complex syndrome with multiple domains including symptoms, lung function, asthma control, and airway inflammation. A study of Fenom PRO™, a novel monitor for exhaled nitric oxide (FeNO), provided an opportunity to look at concordance/discordance (C/D) for changes in multiple asthma domains over a 2-week period after corticosteroid therapy.

    Methods

    Non-steroid-treated adults and children with uncontrolled asthma had asthma domain measures, (FeNO), forced expired volume in 1 s (FEV1), the 6-item Asthma Control Questionnaire scores (ACQ6), and daily asthma symptoms, assessed before and after a 2-week course of corticosteroids.

    The pulmonary sequalae in discharged patients with COVID-19: a short-term observational study

    Respiratory Research Research- Open Access
    Dehan Liu, Wanshu Zhang, Feng Pan, Lin Li, Lian Yang, Dandan Zheng, Jiazheng Wang & Bo Liang Respiratory Research volume 21, Article number: 125 (2020)
    Abstract

    Background

    A cluster of patients with coronavirus disease 2019 (COVID-19) pneumonia were discharged from hospitals in Wuhan, China. We aimed to determine the cumulative percentage of complete radiological resolution at each time point, to explore the relevant affecting factors, and to describe the chest CT findings at different time points after hospital discharge.

    Methods

    Patients with COVID-19 pneumonia confirmed by RT-PCR who were discharged consecutively from the hospital between 5 February 2020 and 10 March 2020 and who underwent serial chest CT scans on schedule were enrolled.

    May 23, 2020

    Sialylation of immunoglobulin E is a determinant of allergic pathogenicity

    Abstract
    Approximately one-third of the world’s population suffers from allergies1. Exposure to allergens crosslinks immunoglobulin E (IgE) antibodies that are bound to mast cells and basophils, triggering the release of inflammatory mediators, including histamine2. Although IgE is absolutely required for allergies, it is not understood why total and allergen-specific IgE concentrations do not reproducibly correlate with allergic disease3,4,5. It is well-established that glycosylation of IgG dictates its effector function and has disease-specific patterns. However, whether IgE glycans differ in disease states or affect biological activity is completely unknown6. Here we perform an unbiased examination of glycosylation patterns of total IgE from individuals with a peanut allergy and from non-atopic individuals without allergies.